VYNDAMAX (tafamidis) 1 Health Professional Information

Medical Information

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?


VYNDAMAX (tafamidis) is indicated for:

  • the treatment of adult patients with cardiomyopathy due to transthyretin-mediated amyloidosis (ATTR-CM), wild type or hereditary, to reduce cardiovascular mortality and cardiovascular related hospitalization. 

1.1    Pediatrics

Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 

1.2    Geriatrics

Geriatrics (≥65 years of age): Safety and efficacy were demonstrated in this population.